TVT 004
Alternative Names: TVT-004Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Travecta Therapeutics
- Class Non-opioid analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain; Pain
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Neuropathic-pain in Singapore (PO)
- 28 Dec 2024 No recent reports of development identified for preclinical development in Pain in Singapore (PO)
- 09 Jun 2021 Travecta Therapeutics plans a first-in-human phase I clinical trial in Pain (PO) in the fourth quarter of 2022